Envestnet Asset Management Inc. Sells 15,910 Shares of Haemonetics Corporation $HAE

Envestnet Asset Management Inc. cut its stake in Haemonetics Corporation (NYSE:HAE) by 28.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,836 shares of the medical instruments supplier’s stock after selling 15,910 shares during the quarter. Envestnet Asset Management Inc. owned about 0.08% of Haemonetics worth $2,972,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of HAE. M&T Bank Corp purchased a new position in shares of Haemonetics during the first quarter valued at about $243,000. Cerity Partners LLC boosted its position in Haemonetics by 32.5% during the 1st quarter. Cerity Partners LLC now owns 11,058 shares of the medical instruments supplier’s stock valued at $703,000 after acquiring an additional 2,713 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Haemonetics by 1.4% during the 1st quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the medical instruments supplier’s stock worth $896,000 after acquiring an additional 200 shares during the period. Segall Bryant & Hamill LLC bought a new position in shares of Haemonetics in the 1st quarter worth approximately $1,361,000. Finally, Verdence Capital Advisors LLC raised its position in shares of Haemonetics by 59.1% in the 1st quarter. Verdence Capital Advisors LLC now owns 6,002 shares of the medical instruments supplier’s stock worth $381,000 after acquiring an additional 2,229 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on HAE shares. Mizuho dropped their price target on Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. JPMorgan Chase & Co. restated a “neutral” rating and set a $62.00 target price (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Raymond James Financial reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research report on Friday. Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Finally, Needham & Company LLC boosted their price objective on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $79.70.

Haemonetics Price Performance

HAE opened at $73.48 on Friday. The firm has a market cap of $3.44 billion, a PE ratio of 22.47, a P/E/G ratio of 0.91 and a beta of 0.43. The stock has a 50-day moving average price of $53.39 and a 200-day moving average price of $62.48. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $91.43. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. The company had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. Haemonetics’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Sell-side analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.